The immediate reaction to the Colossal Biosciences’ claims from a broad section of the scientific community was highly ...

Asahi Kasei Life Science expects to offer the bioindustry more agile and focused services and deeper innovation in bioprocess ...

GEN editors discuss Colossal's dire wolves, the impacts of tariffs on biotech, and the sweeping government layoffs and leadership departures.

Cachexia not only contributes to reduced quality of life but also limits a patient’s ability to tolerate or benefit from standard treatments.

The PRRDetect algorithm identifies tumors with faulty DNA repair mechanisms known as post-replicative repair dysfunction or PRRd.

Immediate use for the newly developed assembloids could include studying neurodevelopmental disorders such as autism.

To prevent dominance by an acknowledged adversary, the National Security Commission on Emerging Biotechnology (NSCEB) calls for a two-track strategy that helps American companies innovate more quickly ...

Kiji Therapeutics Engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.

Emerging AI-based technologies are galvanizing a new generation of data-driven machinery in the biopharmaceutical industry.

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

The Cell Shuttle was designed to help academic cell therapy developers by providing an integrated, automated solution.

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.